A major international randomized controlled trial (RCT) has just been published in the internationally recognized journal The Lancet Diabetes & Endocrinology and documents the effect of a new treatment, LeucoPatch®, which offers significant enhancement of healing of hard-to-heal foot ulcers.
The Danish medtech company Reapplix has paved the way for commercialization of its new technology, LeucoPatch®, which may save patients with hard-to-heal foot ulcers from amputations and the related risk of premature death
A newly published RCT shows that LeucoPatch® has a significantly better effect on chronic diabetic foot ulcers than standard care. The study, which was the first of its kind, was published this week in The Lancet Diabetes & Endocrinology
In Denmark alone, 22,000 people suffer from diabetic foot ulcers, resulting in approximately 1,000 amputations each year, and a total estimated health economic cost of 5 billion DKK
The marketing of LeucoPatch® technology has begun in Denmark. Reapplix holds the patents and the global rights to LeucoPatch®
Reapplix is now primed to market its novel product LeucoPatch®. This provides new hope to people globally who suffer from very hard to heal diabetic foot ulcers. Paving the way for this milestone are the results of an international five-year research project showing that LeucoPatch® has a significantly better effect on chronic diabetic foot ulcers than traditional treatment. The results have just been published in the internationally recognized journal The Lancet Diabetes & Endocrinology and are to be presented at the Diabetic Foot Study Group Conference 28-30 September 2018, and at the annual meeting of the European Association for the Study of Diabetes (EASD), 1-5 October 2018, both in Berlin.